Related Experiment Video
Updated: Nov 16, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer]
Felix Gronau1, Maximilian Jara1, Linda Feldbrügge1
1Chirurgische Klinik Campus Charité Mitte | Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin, Deutschland.
Background:
Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival.
Methods:
This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis.
Results:
The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7 months under palliative second-line systemic treatment. The median survival time increased to 12 months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies.
Expert Opinion:
Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers.
